Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Feldman Website

Steven A. Feldman, Ph.D.

Selected Publications

1)  Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, Restifo NP, Feldman SA, Rosenberg SA, Morgan RA.
A novel chimeric antigen receptor against PSCA mediates tumor destruction in a humanized mouse model of pancreatic cancer.
Hum. Gene Ther. 2014.
[Journal]
2)  Rosati SF, Parkhurst MR, Hong Y, Zheng Z, Feldman SA, Rao M, Abate-Daga D, Beard RE, Xu H, Black MA, Robbins PF, Schrump DA, Rosenberg SA, Morgan RA.
A Novel Murine T-Cell Receptor Targeting NY-ESO-1.
J. Immunother. 37: 135-146, 2014.
[Journal]
3)  Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, Feldman SA, Rosenberg SA, Morgan RA.
Development of a T Cell Receptor Targeting an HLA-A*0201 Restricted Epitope from the Cancer-Testis Antigen SSX2 for Adoptive Immunotherapy of Cancer.
PLoS ONE. 9: e93321, 2014.
[Journal]
4)  Casati A, Varghaei-Nahvi A, Feldman SA, Assenmacher M, Rosenberg SA, Dudley ME, Scheffold A.
Clinical-scale selection and viral transduction of human naïve and central memory CD8(+) T cells for adoptive cell therapy of cancer patients.
Cancer Immunol. Immunother. 2013.
[Journal]
5)  Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA.
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
Blood. 2013.
[Journal]
6)  Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy.
J. Immunother. 36: 133-51, 2013.
[Journal]
7)  Yang S, Karne NK, Goff SL, Black MA, Xu H, Bischof D, Cornetta K, Rosenberg SA, Morgan RA, Feldman SA.
A Simple and Effective Method to Generate Lentiviral Vectors for ex Vivo Gene Delivery to Mature Human Peripheral Blood Lymphocytes.
Hum Gene Ther Methods. 23: 73-83, 2012.
[Journal]
8)  Zhang L, Feldman SA, Zheng Z, Chinnasamy N, Xu H, Nahvi AV, Dudley ME, Rosenberg SA, Morgan RA.
Evaluation of γ-Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical Application.
J. Immunother. 35: 430-9, 2012.
[Journal]
9)  Morgan RA, Johnson LA, Davis J, Zheng Z, Woolard K, Feldman SA, Chinnasamy N, Kuan C, Song H, Zhang W, Fine HA, Rosenberg SA.
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
Hum Gene Ther. 23: 1043-53, 2012.
[Journal]
10)  Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME, Feldman SA, Rosenberg SA, Shurtleff SA, Rooney CM, Heslop HE, Dotti G.
Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?.
Mol. Ther. 20: 246-9, 2012.
[Journal]
11)  Friedman KM, Devillier LE, Feldman SA, Rosenberg SA, Dudley ME.
Augmented Lymphocyte Expansion from Solid Tumors With Engineered Cells for Costimulatory Enhancement.
J Immunother. 34: 651-61, 2011.
[Journal]
12)  Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DN, Morgan RA, Laurencot C, Rosenberg SA.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Blood. 119: 2709-20, 2011.
[Journal]
13)  Wang QJ, Hanada K, Feldman SA, Zhao Y, Inozume T, Yang JC.
Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma.
J Immunol Methods. 366: 43-51, 2011.
[Journal]
14)  Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CR, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA.
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1.
J Clin Oncol. 29: 917-24, 2011.
[Journal]
15)  Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, Feldman SA, Ferrone S, Rosenberg SA, Morgan RA.
A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas.
Cancer Res. 70: 3027-33, 2010.
[Journal]
16)  Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, Hong JJ, Parkhurst MR, Feldman SA, Schrump DS, Restifo NP, Robbins PF, Rosenberg SA, Morgan RA.
A TCR Targeting the HLA-A*0201-Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer.
J Immunol. 186: 685-96, 2010.
[Journal]
17)  Goff SL, Johnson LA, Black MA, Xu H, Zheng Z, Cohen CJ, Morgan RA, Rosenberg SA, Feldman SA.
Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion.
Cancer Immunol. Immunother. 59: 1551-60, 2010.
[Journal]
18)  Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DN, Lanier BJ, Morgan RA, Rosenberg SA.
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19.
Blood. 116: 4099-102, 2010.
[Journal]
19)  Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA.
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.
J. Clin. Invest. 120: 3953-68, 2010.
[Journal]
20)  Feldman SA, Goff SL, Xu H, Black MA, Kochenderfer JN, Johnson LA, Yang JC, Wang Q, Parkhurst MR, Cross SB, Morgan RA, Cornetta K, Rosenberg SA.
Rapid Production of Clinical-Grade Gammaretroviral Vectors in Expanded Surface Roller Bottles using a.
Hum Gene Ther. 22: 107-15, 2010.
[Journal]
21)  Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DN, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA.
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis.
Mol Ther. 19: 620-6, 2010.
[Journal]
22)  Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA.
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor.
J Immunother. 32: 689-702, 2009.
[Journal]
23)  Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, Feldman SA, Johnson LA, Bennett AD, Dunn SM, Mahon TM, Jakobsen BK, Rosenberg SA.
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.
J. Immunol. 180: 6116-31, 2008.
[Journal]
24)  Crim RL, Audet SA, Feldman SA, Mostowski HS, Beeler JA.
Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity.
J. Virol. 81: 261-71, 2007.
[Journal]
25)  Feldman SA, Farrell KB, Murthy RK, Russ JL, Eiden MV.
Identification of an extracellular domain within the human PiT2 receptor that is required for amphotropic murine leukemia virus binding.
J. Virol. 78: 595-602, 2004.
[Journal]
26)  Feldman SA, Eiden LE.
The chromogranins: their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia.
Endocr. Pathol. 14: 3-23, 2003.
[Journal]
27)  Faix PH, Feldman SA, Overbaugh J, Eiden MV.
Host range and receptor binding properties of vectors bearing feline leukemia virus subgroup B envelopes can be modulated by envelope sequences outside of the receptor binding domain.
J. Virol. 76: 12369-75, 2002.
[Journal]
28)  Feldman SA, Crim RL, Audet SA, Beeler JA.
Human respiratory syncytial virus surface glycoproteins F, G and SH form an oligomeric complex.
Arch. Virol. 146: 2369-83, 2001.
[Journal]
29)  Kutza J, Crim L, Feldman S, Hayes MP, Gruber M, Beeler J, Clouse KA.
Macrophage colony-stimulating factor antagonists inhibit replication of HIV-1 in human macrophages.
J. Immunol. 164: 4955-60, 2000.
[Journal]
30)  Feldman SA, Audet S, Beeler JA.
The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate.
J. Virol. 74: 6442-7, 2000.
[Journal]
31)  Feldman SA, Hendry RM, Beeler JA.
Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G.
J. Virol. 73: 6610-7, 1999.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 4/4/2014.